Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Raynaud Disease

ClinicalTrials.gov lists 81 trials for Raynaud Disease or a narrower condition beneath it. MediQuest Therapeutics has the most among industry and government lead sponsors, with 8.

MeSH D011928 Cardiovascular Diseases C14 C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 15 Phase 4 Phase 4 6 Not applicable Not applicable 21 Observational Observational 11 Phase 1 Phase 1 5 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 17 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 15 Phase 4 Phase 4 6 Not applicable Not applicable 21 Observational Observational 11

Trials per phase (log scale)

80 of the 81 trials are tagged with Raynaud Disease itself; the rest are tagged with a narrower condition beneath it.

Get the Raynaud Disease report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Raynaud Disease trials start? (25)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 7

1992: 1 trials (Phase 3 1) 1995: 1 trials (Phase 3 1) 2001: 3 trials (Phase 4 2, Phase 2 1) 2004: 2 trials (Not applicable 1, Phase 2/3 1) 2005: 2 trials (Phase 3 1, Phase 2 1) 2006: 3 trials (Phase 3 1, Phase 2/3 1, Phase 2 1) 2007: 6 trials (Phase 3 4, Phase 2 2) 2008: 2 trials (Not applicable 1, Phase 1 1) 2009: 3 trials (Phase 3 2, Phase 1 1) 2010: 2 trials (Not applicable 1, Phase 2 1) 2011: 5 trials (Not applicable 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2012: 1 trials (Not applicable 1) 2013: 2 trials (Phase 2/3 1, Phase 2 1) 2014: 6 trials (Observational 1, Not applicable 2, Phase 2/3 1, Phase 2 2) 2015: 7 trials (Observational 2, Not applicable 2, Phase 3 1, Phase 2 1, Phase 1/2 1) 2016: 5 trials (Not applicable 3, Phase 1 2) 2017: 2 trials (Not applicable 2) 2018: 4 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 1) 2019: 5 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 1) 2020: 5 trials (Observational 1, Not applicable 2, Phase 2 1, Phase 1 1) 2021: 3 trials (Observational 2, Phase 2 1) 2022: 4 trials (Not applicable 2, Phase 4 1, Phase 2 1) 2023: 2 trials (Observational 2) 2025: 2 trials (Not applicable 1, Phase 4 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2
2025 2
2023 2
2022 4
2021 3
2020 5
2019 5
2018 4
2017 2
2016 5

No forecast is made for this condition: it averages 1.8 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Raynaud Disease trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 5
Phase 1/2 1
Phase 2 17
Phase 2/3 5
Phase 3 15
Phase 4 6
Not applicable 21
Observational 11

How many Raynaud Disease trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 3
Recruiting 3
Completed 52
Terminated 7
Withdrawn 4

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Raynaud Disease trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
MediQuest Therapeutics 8
Civi Biopharma, Inc. 2
Otsuka America Pharmaceutical 2
Pfizer 2
Sanjay Gandhi Postgraduate Institute of Medical Sciences 2

Which drugs are being tested for Raynaud Disease? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Nitroglycerin 4
SILDENAFIL 2
Cilostazol 2
Botulinum Toxin 2

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Tadalafil Pill 4
type A botulinum toxin 3
Iloprost Injection, for intravenous use 2
Topical organogel with nitroglycerin 2
Sham device 2

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Raynaud Disease trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Infection 3 1
Broken bone 1 1
Collapsed Lung 1 1
Dizziness 1 1
Facial edema 1 1

Which publications cover Raynaud Disease? (130)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Sub-conditions in MeSH (1)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages